Wyeth Plans Three NDA Filings By April
This article was originally published in The Pink Sheet Daily
Executive Summary
Among the anticipated filings is Torisel (temsirolimus) for advanced renal cell cancer, bifeprunox for schizophrenia and methylnaltrexone for opiod-induced side effects.